P-053 - EVALUATION OF LACTATE DEHYDROGENASE (LDH) AS A MARKER FOR LORLATINIB EFFICACY IN PATIENTS WITH ADVANCED ALK-POSITIVE NON-SMALL CELL LUNG CANCER (NSCLC).

M. Dinh¹, Y. Pithavala¹, J. Chen²; ¹Pfizer Inc., San Diego, CA, USA, ²Pfizer Inc., San Francisco, CA, USA.

Presenting Author(s)